secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001493152-23-022243
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air reports $59.4M net loss for FY2023; secures $40M debt facility
-------------------------------------------------------------------------

- GAAP net loss of $59.4M ($55.8M attributable, $1.86 per share) vs $43.2M ($1.68) prior year.
- Cash, cash equivalents and marketable securities of $45.9M as of March 31, 2023.
- Secured up to $40M debt financing from Avenue Capital; $17.5M funded at 12% or Prime+3.75% with warrants.
- Completed phase 1 of LungFit PH commercial launch; shifted to phase 2; CE Mark and FDA label expansion expected in 2023.
- Licensed nNOS inhibitors from Hebrew University for autism; first-in-human study planned in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223022243/0001493152-23-022243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223022243/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-022243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer